下咽癌中差异表达的蛋白激酶及抑制剂的研究进展

在头颈恶性肿瘤中,下咽癌恶性程度高,患者生存质量较差且通常预后不良。下咽癌的治疗采用手术为主的方式,并辅助以放化疗。术后患者喉功能受损严重,寻找能够尽量保护喉功能的治疗方法是目前研究的重点。靶向治疗对下咽癌患者保护喉功能、提高生存质量意义重大。研究发现,下咽癌发生过程中涉及多种蛋白激酶介导的信号通路及基因,对可能在这一过程中有重要意义的蛋白激酶PKC-β、CDK4/6、Cdc42、Rac1、STK33、CK2和PHLPP作一综述,以期为蛋白激酶抑制剂作为下咽癌治疗的靶点提供新的方向。

Research progress on differentially-expressed protein kinases and inhibitors in hypopharyngeal carcinoma

Among tumors of the head and neck,hypopharyngeal cancer is highly malignant and patients suffering from it have a poor quality of life,usually with a poor prognosis.Surgery is the main method of treatment of hypopharyngeal cancer,assisted by radiotherapy and chemotherapy.After surgery,the patient's laryngeal function is seriously impaired.Finding a treatment method that can protect the laryngeal function as much as possible is the focus of current research.Targeted therapy is of great significance to protecting the laryngeal function and improving the quality of life of patients with hypopharyngeal carcinoma.The study found that a variety of protein-kinase-mediated signaling pathways and genes are involved in the development of this pathology.Now,protein kinases PKC-β,CDK4/6,Cdc42,Rac1,and STK33,which might have an important role in this process,CK2 and PHLPP are reviewed.There is hope that protein kinase inhibitors would provide new directions for the treatment of hypopharyngeal cancer.